![]() As of 10 November 2021, an estimated 24.2 million first doses of the COVID-19 Pfizer/BioNTech Vaccine and 24.8 million first doses of the COVID-19 Vaccine AstraZeneca had been administered, and around 20.6 million and 24.1 million second doses of COVID-19 Pfizer/BioNTech Vaccine and COVID-19 Vaccine AstraZeneca respectively. This safety update report is based on detailed analysis of data up to 10 November 2021. This is particularly the case when millions of people are vaccinated, and especially when vaccines are being given to the most elderly people and people who have underlying illness. Some events may have happened anyway, regardless of vaccination. The nature of Yellow Card reporting means that reported events are not always proven side effects. Any member of the public or health professional can submit suspected side effects through the Yellow Card scheme. Part of our monitoring role includes reviewing reports of suspected side effects. We also work closely with our public health partners in reviewing the effectiveness and impact of the vaccines to ensure the benefits continue to outweigh any possible side effects. We have in place a proactive strategy to do this. The MHRA continually monitors safety during widespread use of a vaccine. Adverse reactions were reported less frequently in older adults (over 65 years) than in younger people. These reactions were usually mild or moderate in intensity and resolved within a few days after vaccination. The most frequent adverse reactions in these trials were pain at the injection site, fatigue, headache, myalgia (muscle pains), arthralgia (joint pains), chills, nausea/vomiting, axillary swelling/tenderness (swelling/tenderness of glands in the armpit), fever, injection site swelling and redness these were each reported in more than 1 in 10 people. The COVID-19 Vaccine Moderna was evaluated in clinical trials involving more than 30,000 participants. Adverse reactions were generally milder and reported less frequently in older adults (65 years and older) than in younger people. Adverse reactions reported after the second dose were milder and reported less frequently than after the first dose. ![]() The majority of adverse reactions were mild to moderate in severity and usually resolved within a few days of vaccination. The most frequently reported adverse reactions in these trials were injection-site tenderness, injection-site pain, headache, fatigue, myalgia, malaise, pyrexia (fever), chills, arthralgia, and nausea these were each reported in more than 1 in 10 people. The COVID-19 Vaccine AstraZeneca was evaluated in clinical trials involving more than 23,000 participants. Adverse reactions were reported less frequently in older adults (over 55 years) than in younger people. The most frequent adverse reactions in trials were pain at the injection site, fatigue, headache, myalgia (muscle pains), chills, arthralgia (joint pains), and fever these were each reported in more than 1 in 10 people. The COVID-19 Pfizer/BioNTech Vaccine was evaluated in clinical trials involving more than 44,000 participants. These side effects need to be continuously balanced against the expected benefits in preventing illness. ![]() Following review of data for the COVID-19 Vaccine Moderna, the MHRA and CHM experts also concluded that this vaccine can be used as a safe and effective booster dose.Īll vaccines and medicines have some side effects. The MHRA confirmed on 9 September 2021 that the COVID-19 vaccines made by Pfizer and AstraZeneca can be used as safe and effective booster doses. Data are now available on the impact of the vaccination campaign in reducing infections and illness in the UK. In clinical trials, the vaccines showed very high levels of protection against symptomatic infections with COVID-19. ![]() All have been authorised for supply by the Medicines and Healthcare products Regulatory Agency ( MHRA) following a thorough review of safety, quality and efficacy information from clinical trials. Three COVID-19 vaccines, the COVID-19 Pfizer/BioNTech Vaccine, COVID-19 Vaccine AstraZeneca and COVID-19 Vaccine Moderna, are currently being used in the UK. A national immunisation campaign has been underway since early December 2020. Vaccination is the single most effective way to reduce deaths and severe illness from COVID-19. SummaryĪt the time of this report, over 142,753 people across the UK have died within 28 days of a positive test for coronavirus (COVID-19). This report covers the period 9 December 2020 to 10 November 2021. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |